GU Cancers Symposium

Acute toxicity rates similar for SBRT, conventional XRT

March 07, 2019

Stereotactic body radiotherapy shows rates of acute toxicity that are similar to those of conventionally fractionated radiotherapy in men with low- or intermediate-risk localized prostate cancer, according to early findings from an international randomized study.

Personalized medicine key to improving MIBC treatment

March 05, 2019

While neoadjuvant chemotherapy has been associated with a survival benefit in patients with muscle-invasive bladder cancer, patient selection needs to improve to optimize clinical outcomes and minimize costs, according to Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas.

Large database reveals surprises in mCRPC management

March 05, 2019

Analysis of a large, real-world patient database reveals interesting findings about the current management of metastatic castration-resistant prostate cancer, including a few surprises. Celestia Higano, MD, said 77% of patients received first-line therapy.

Data help define relationship between HPV, bladder cancer

February 28, 2019

“HPV6 positive serology was associated with an increased odds of bladder cancer, and I saw a trend in that it was younger patients with bladder cancer who had the HPV6 positivity,” says Lael S. Reinstatler, MD, MPH, in this video interview.

Genomic test predicts PCa outcomes in African-American men

February 28, 2019

The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.

Coming soon: Experts discuss GU Cancers Symposium highlights

February 26, 2019

Urology Times video interviews will feature expert discussion on prostate, kidney, and bladder cancer research from the Genitourinary Cancers Symposium in San Francisco.